Results from evoke and evoke+: Two phase 3, randomised, placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer’s disease
Authors:
Jeffrey L. Cummings1, Alireza Atri2–4, Howard H. Feldman5, Mary Sano6,7, Henrik Zetterberg8, Filip K. Knop9, Peter Johannsen9, Teresa León9, Rikke Mortensen Abschneider9, Philip Scheltens10,11